Stereotactic Radiosurgery for Cancer-Related Spinal Cord Compression

Recruiting in Palo Alto (17 mi)

Overseen byBenjamin Spieler, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Miami

No Placebo Group

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to see if treating cancer with the magnetic resonance imaging guided adaptive radiotherapy (MRIdian) can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).

Research Team

Benjamin Spieler, MD

Principal Investigator

University of Miami

Eligibility Criteria

Adults over 18 with a good performance status and prognosis of living more than 3 months, who have solid tumors pressing on the spinal cord that could be treated with surgery. They must be able to walk, handle daily MRI scans, use contraception for 6+ months post-therapy, and give informed consent. Excluded are those with certain sensitive tumor types, rapid neurological decline or unrelated neuro problems.

Inclusion Criteria

I have a solid tumor with spinal cord compression and surgery is an option.

You are expected to live for at least 3 more months.

Your pain level, as measured on a scale, needs to be within a certain range in the week before you join the study.

See 16 more

Exclusion Criteria

You cannot have an MRI.

I am unable to make medical decisions for myself.

My neurological condition is worsening quickly.

See 6 more

Treatment Details

Interventions

ViewRay MRIdian Stereotactic Radiosurgery (Radiation)

Trial OverviewThe trial is testing if MRIdian Stereotactic Radiosurgery can control tumors in the spine without needing surgery. This involves using advanced imaging (MRI) to guide precise radiation therapy aimed at relieving pressure on the spinal cord caused by cancer.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: ViewRay MRidianExperimental Treatment1 Intervention

Participants will receive five (5) doses of radiation therapy over four (4) weeks. The first dose will be given during week 1; after at least 36 hours from the first dose, participants will receive the second dose. The remaining doses will be three (3) doses will be administered once per week during weeks 2, 3, and 4. The treatment plan may change at the discretion of the treating physician. Participants will have three additional doses each week in Weeks 2, 3, and 4.